Claims for Patent: 7,850,970

Summary for Patent: 7,850,970

Title:	Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
Abstract:	A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.
Inventor(s):	Shapiro; Leland (Denver, CO)
Assignee:	The Regents of the University of Colorado (Denver, CO)
Application Number:	10/926,051
Patent Claims:	1. A method for inhibiting Bacillus anthracis or Bacillus anthracis toxin infection in a patient comprising, administering a therapeutically effective amount of a composition of one or more peptides selected from the group consisting of AGAMFLEAIP (SEQUENCE ID NO. 56); MSIPPEVKFN (SEQUENCE ID NO. 57); KPFVFLMIEQ (SEQUENCE ID NO. 58); NTKSPLFMGK (SEQUENCE ID NO. 59); and combinations thereof, to inhibit at least one of lethal factor (LF) and edema factor (EF) transport into cells of the patient. 2. The method of claim 1, wherein exposure to Bacillus anthracis toxin is from inhalation anthrax, cutaneous anthrax, gastrointestinal anthrax or a combination thereof. 3. The method of claim 1, wherein the patient is exposed to cutaneous Bacillus anthracis and the patient is administered at least one of a topical or systemic therapeutically effective amount of the composition. 4. The method of claim 1, wherein the patient is exposed to Bacillus anthracis-toxin from exposure to inhalation anthrax and the patient is administered at least one of an inhalable or systemic therapeutically effective amount of the composition. 5. The method of claim 1, wherein the patient is exposed to Bacillus anthracis-toxin from exposure to gastrointestinal anthrax and the patient is administered at least one of an oral or systemic therapeutically effective amount of the composition. 6. The method of claim 1, wherein administration to the patient reduces anthrax infection of the patient compared to a control patient. 7. The method of claim 1, further comprising administering one or more anti-bacterial agents to the patient. 8. A method for inhibiting Bacillus anthracis or Bacillus anthracis toxin infection in a patient comprising, administering a therapeutically effective amount of a composition of one or more peptides selected from the group consisting of AGAMFLEAIP (SEQUENCE ID NO. 56); MSIPPEVKFN (SEQUENCE ID NO. 57); KPFVFLMIEQ (SEQUENCE ID NO. 58); NTKSPLFMGK (SEQUENCE ID NO. 59); and combinations thereof. 9. The method of claim 8, wherein the peptides are MSIPPEVKFN (SEQUENCE ID NO. 57); KPFVFLMIEQ (SEQUENCE ID NO. 58) or a combination thereof. 10. A method for inhibiting Bacillus anthracis or Bacillus anthracis toxin infection in a patient comprising, administering a therapeutically effective amount of a composition of one or more peptides selected from the group consisting of AGAMFLEAIP (SEQUENCE ID NO. 56); MSIPPEVKFN (SEQUENCE ID NO. 57); KPFVFLMIEQ (SEQUENCE ID NO. 58); NTKSPLFMGK (SEQUENCE ID NO. 59); and combinations thereof, to inhibit protective antigen (PA) processing of Bacillus anthracis toxin in the patient's cells. 11. The method of claim 10, wherein the one or more peptides are MSIPPEVKFN (SEQUENCE ID NO. 57), KPFVFLMIEQ (SEQUENCE ID NO. 58) or a combination thereof.

Details for Patent 7,850,970

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2040-01-28